Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer.
GATA3
NC9
Transglutaminase variants
breast cancer
drug resistance
Journal
International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
06
2021
accepted:
30
09
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
29
3
2022
Statut:
epublish
Résumé
The role of transglutaminase type 2 in cell physiology is related to protein transamidation and signal transduction (affecting extracellular, intracellular and nuclear processes) aided by the expression of truncated isoforms and of two lncRNAs with regulatory functions. In breast cancer TG2 is associated with disease progression supporting motility, epithelial-mesenchymal transition, invasion and drug resistance. The aim of his work is to clarify these issues by emphasizing the interconnections among
Identifiants
pubmed: 34975314
doi: 10.7150/ijbs.64167
pii: ijbsv18p0001
pmc: PMC8692156
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
GATA3 Transcription Factor
0
GATA3 protein, human
0
Doxorubicin
80168379AG
Protein Glutamine gamma Glutamyltransferase 2
EC 2.3.2.13
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-14Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Mol Cancer Ther. 2014 May;13(5):1078-91
pubmed: 24634413
Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18357-61
pubmed: 19826084
Haematologica. 2019 Mar;104(3):505-515
pubmed: 30237268
Breast Cancer Res. 2013 Feb 25;15(1):202
pubmed: 23673317
Respir Res. 2018 Apr 4;19(1):55
pubmed: 29615049
Carcinogenesis. 2008 Mar;29(3):510-8
pubmed: 18174247
Biochem J. 1995 Jun 1;308 ( Pt 2):513-9
pubmed: 7772035
Cancer Biol Ther. 2018 Apr 3;19(4):271-281
pubmed: 29053396
Amino Acids. 2019 Sep;51(9):1273-1288
pubmed: 31440819
Am J Cancer Res. 2015 Aug 15;5(9):2756-76
pubmed: 26609482
J Phys Chem B. 2014 Feb 6;118(5):1288-95
pubmed: 24417409
Expert Opin Ther Targets. 2011 Oct;15(10):1197-210
pubmed: 21838596
FEBS J. 2011 Dec;278(24):4717-39
pubmed: 21902809
Oncotarget. 2015 Aug 21;6(24):20525-39
pubmed: 25971211
J BUON. 2005 Jan-Mar;10(1):81-7
pubmed: 17335136
Mol Cancer Ther. 2012 Apr;11(4):873-87
pubmed: 22294718
Sci Rep. 2019 Jul 1;9(1):9414
pubmed: 31263158
J Biol Chem. 2010 Feb 5;285(6):3561-3567
pubmed: 20007697
Lab Invest. 2005 Jan;85(1):154-9
pubmed: 15543203
Exp Ther Med. 2015 Oct;10(4):1413-1418
pubmed: 26622499
PLoS One. 2013 Sep 13;8(9):e74437
pubmed: 24058567
Adv Enzymol Relat Areas Mol Biol. 2011;78:1-46
pubmed: 22220471
PLoS One. 2011;6(6):e20701
pubmed: 21687668
Nat Struct Mol Biol. 2010 Nov;17(11):1358-66
pubmed: 20972445
BMC Cancer. 2014 Apr 22;14:278
pubmed: 24758297
J Cancer. 2017 Sep 12;8(16):3131-3141
pubmed: 29158785
Cancers (Basel). 2020 Mar 11;12(3):
pubmed: 32168763
Amino Acids. 2018 Apr;50(3-4):421-438
pubmed: 29313085
Mol Carcinog. 2019 Jun;58(6):837-853
pubmed: 30693974
J Hematol Oncol. 2017 Jun 2;10(1):114
pubmed: 28576130
Neoplasia. 2016 Nov;18(11):689-698
pubmed: 27792935
Cancer Res. 2008 Jul 15;68(14):5849-58
pubmed: 18632639
Amino Acids. 2013 Jan;44(1):63-72
pubmed: 22130737
Lab Invest. 1996 Nov;75(5):637-45
pubmed: 8941210
Cell. 2007 May 18;129(4):823-37
pubmed: 17512414
Physiol Rev. 2014 Apr;94(2):383-417
pubmed: 24692352
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18682-7
pubmed: 18003922
Oncogenesis. 2020 Feb 13;9(2):16
pubmed: 32054828
Nat Commun. 2016 Feb 02;7:10406
pubmed: 26832224
Mol Cancer Ther. 2007 Mar;6(3):1089-98
pubmed: 17363502
Cancer Res. 2006 Nov 15;66(22):10936-43
pubmed: 17108131
Cancer Genomics Proteomics. 2017 Nov-Dec;14(6):409-425
pubmed: 29109091
BMC Biol. 2019 Jul 30;17(1):62
pubmed: 31362726
Mol Cells. 2012 Mar;33(3):235-41
pubmed: 22382681
Front Oncol. 2014 Sep 03;4:221
pubmed: 25232533
Oncotarget. 2018 Oct 2;9(77):34495-34505
pubmed: 30349644
Oncogene. 2017 May 25;36(21):2981-2990
pubmed: 27941875
BMC Cancer. 2016 Sep 08;16(1):724
pubmed: 27609180
Oncogene. 2006 May 18;25(21):3049-58
pubmed: 16449978
Biochim Biophys Acta. 2014 Jan;1845(1):84-9
pubmed: 24361676
Neurotoxicology. 2018 Jul;67:296-304
pubmed: 29966605
Mol Cancer. 2010 Mar 25;9:68
pubmed: 20338046
Nat Struct Mol Biol. 2020 Dec;27(12):1165-1177
pubmed: 33046905
J Biol Chem. 2004 Oct 1;279(40):41461-7
pubmed: 15272014
Biochem J. 2018 May 15;475(9):1643-1667
pubmed: 29764956
Neuro Oncol. 2017 Feb 1;19(2):208-218
pubmed: 27591334
Genome Biol. 2020 Feb 21;21(1):45
pubmed: 32085783
Sci Rep. 2019 Nov 22;9(1):17335
pubmed: 31758034
Front Biosci (Landmark Ed). 2013 Jan 01;18:504-19
pubmed: 23276939
Breast Cancer Res Treat. 2013 Jan;137(2):329-36
pubmed: 23224146
Trends Pharmacol Sci. 2015 Jan;36(1):32-40
pubmed: 25500711
Breast Cancer (Auckl). 2010 May 20;4:35-41
pubmed: 20697531
Biochem Biophys Res Commun. 2018 Apr 6;498(3):509-515
pubmed: 29510139